MedTrace Logo

Human Amniotic Epithelial Cells for Treatment of Bronchial Fistula

NCT02959333 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-11-09

No results posted yet for this study

Summary

Bronchial fistula (BF), an abnormal passage or communication between a bronchus and another part of the body, may develop when there are penetrating wounds of the thorax and after lung surgery. Without effective therapy, treatment of BF is a challenge, with a high rate of mortality and teratogenicity.

The investigators will conduct endoscopic injection of human amniotic epithelial cells to fistula, observe the recovery of bronchial fistula and systemic reactions, to investigate the application of human amniotic epithelial cells in the treatment of bronchial fistula.

Conditions

  • Bronchial Fistula

Interventions

BIOLOGICAL

hAEC

hAEC: human amniotic epithelial cells

Sponsors & Collaborators

  • Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

    collaborator INDUSTRY

  • The Second Affiliated Hospital of Fujian Medical University

    lead OTHER

Principal Investigators

  • Yimin Zeng, Dr. · The Second Affiliated Hospital of Fujian Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-10-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02959333 on ClinicalTrials.gov